NEW YORK (GenomeWeb News) – Biogen said this week that Philip Sharp will retire from his post on the company's board of directors. Sharp is Institute Professor at the Massachusetts Institute of Technology and a faculty member in the Department of Biology and at the Center for Cancer Research. He also has been director of the McGovern Institute for Brain Research at MIT, and he was awarded a Nobel Prize in Medicine in 1993. Sharp co-founded the company in 1978 and he has served as a director since 1982. He also is a co-founder of RNAi therapeutics firm Alnylam Pharmaceuticals.
Cellexus has appointed Sandy Primrose to serve as a non-executive director. Primrose has held senior management positions at Searle Research and Development and at Amersham International, and he has served in non-executive positions at Codon Pharmaceutical, Adaptive Biosystems, and at the Health Protection Agency.
Rudi Balling will take on the post of Director of the Centre for Systems Biology at the University of Luxembourg. Balling was scientific director of the Helmholtz Center in Braunschweig, and he has been director of the Center for Mammalian Genetics in Munich. He most recently was a guest professor at the Broad Institute of MIT/Harvard University.
Accelrys has named Todd Johnson, who had been serving as interim president and CEO, to be senior VP of marketing and operations. Johnson joined the firm in January, and has worked in the interim role through June. He has been serving as an advisor to the new President and CEO, Max Carnecchia. In the part-time position, Johnson will earn a base salary of $110,000 and will be eligible for a targeted bonus rate of 40 percent.
Delphic Diagnostics has appointed Alun Williams as its new chief executive. He replaces Tim Leaver, who will become a non-executive director, the companion diagnostics developer said.
Promoted? Changing jobs? GenomeWeb wants to know. E-mail [email protected] to appear in People in the News, a weekly roundup of industry comings and goings.